Catheter-based renal sympathetic denervation: long-term Symplicity clinical evidence, new data and future perspectives

With an unrestricted educational grant from MEDTRONIC

Chairpersons: F. Mahfoud, R. Schmieder

Learning Objectives

  • To understand the latest long-term clinical evidence from Symplicity HTN-1 (3-year), Symplicity HTN-2 (2-year) and real-world global SYMPLICITY registry and first-in-man results of Symplicity Spyral
  • To understand the clinical data on the effects of catheter-based renal sympathetic denervation in other disease processes where increased sympathetic tone plays a role in disease pathogenesis
  • To understand the importance of, and the approach to, building new catheter-based renal sympathetic denervation referral networks

Presentations available when logged in:

  • Update on Symplicity clinical trials
  • Update on global SYMPLICITY registry - Where to from here for catheter-based renal sympathetic denervation clinical studies?
  • Expanding to heart failure
  • Symplicity spyral - First-in-man results
  • Extending to stage 1 refractory hypertension
  • Building a successful renal denervation referral networks
  • Introduction and objectives
  • Take-home message